QUANTITY LIMIT CRITERIA
|
|
|
- Penelope Hunter
- 6 years ago
- Views:
Transcription
1 DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS ER (amphetamine extended-release oral suspension) tablets) ADZENYS XR-ODT (amphetamine extended-release orally disintegrating APTENSIO XR CONCERTA tablets) COTEMPLA XR-ODT (methylphenidate extended-release orally disintegrating DAYTRANA (methylphenidate transdermal system) DESOXYN (methamphetamine) DEXTROAMPHETAMINE PRODUCTS (dextroamphetamine) DEXEDRINE SPANSULE (dextroamphetamine sustained-release) DYANAVEL XR ADHD Agents Quantity Limit CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members. CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). Registered trademark of the Blue Cross and Blue Shield Association Page 1 of 8
2 (amphetamine extended-release oral suspension) EVEKEO (amphetamine sulfate) FOCALIN (dexmethylphenidate) FOCALIN XR (dexmethylphenidate extended-release) METADATE CD METHYLIN CHEWABLE TABLET (methylphenidate chewable tablet) METHYLPHENIDATE PRODUCTS (methylphenidate) METHYLPHENIDATE EXTENDED-RELEASE PRODUCTS MYDAYIS (amphetamine mixture extended-release) PROCENTRA (dextroamphetamine sulfate oral solution) QUILLICHEW ER (methylphenidate extended-release chewable tablets) QUILLIVANT XR (methylphenidate extended-release oral suspension) RITALIN LA STRATTERA (atomoxetine) VYVANSE (lisdexamfetamine) ZENZEDI (dextroamphetamine) Page 2 of 8
3 Status: CVS Caremark Criteria Type: Quantity Limit POLICY FDA-APPROVED INDICATIONS Adderall Adderall is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. Adderall XR Adderall XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Adzenys ER Adzenys ER is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. Adzenys XR-ODT Adzenys XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older. Aptensio XR Aptensio XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Concerta Concerta is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65. Cotempla XR-ODT Cotempla XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Daytrana Daytrana is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Desoxyn Desoxyn is indicated for Attention Deficit Disorder with Hyperactivity and Exogenous Obesity. Dexedrine Spansule Dexedrine Spansules are indicated for the treatment of Narcolepsy and Attention Deficit Disorder with Hyperactivity. Dextroamphetamine Dextroamphetamine is indicated for the treatment of Narcolepsy and Attention Deficit Disorder with Hyperactivity. Dyanavel XR Dyanavel XR is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Evekeo Evekeo is indicated for Narcolepsy, Attention Deficit Disorder with Hyperactivity, and Exogenous Obesity. Focalin Page 3 of 8
4 Focalin is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Focalin XR Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged six years and older. Metadate CD Metadate CD is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Methylin Chewable Tablets Methylin Chewable Tablets are indicated for Attention Deficit Disorders and Narcolepsy. Methylphenidate/Methylphenidate Extended-release Methylphenidate and methylphenidate extended-release are indicated for Attention Deficit Disorders and Narcolepsy. Mydayis Mydayis is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older. ProCentra ProCentra is indicated for the treatment of Narcolepsy and Attention Deficit Disorder with Hyperactivity. QuilliChew ER QuilliChew ER is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Quillivant XR Quillivant XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Ritalin LA Ritalin LA is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Strattera Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Vyvanse Vyvanse is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and moderate to severe Binge-Eating Disorder (BED). Zenzedi Zenzedi is indicated for Narcolepsy and Attention Deficit Disorder with Hyperactivity. For all ADHD Agents: Attention Deficit Hyperactivity Disorder (ADHD) A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-V) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; on the go; excessive talking; blurting answers; can t wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Page 4 of 8
5 REFERENCES 1. Adderall [package insert]. Horsham, PA: Teva Pharmaceuticals USA; September Adderall XR [package insert]. Wayne, PA: Shire US Inc.; December Adzenys XR-ODT [package insert]. Grand Prairie, TX: Neos Therapeutics, LP.; February Aptensio XR [package insert]. Coventry, RI: Rhodes Pharmaceuticals L.P.; October Concerta [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; September Daytrana [package insert]. Miami, FL: Noven Therapeutics, LLC; August Desoxyn [package insert]. Lebanon, NJ: Recordati Rare Diseases Inc.; February Dexedrine Spansule [package insert]. Horsham, PA: Amedra Pharmaceuticals, LLC; February Dextroamphetamine sulfate [package insert]. Dayton, NJ: Aurolife Pharma LLC; September Dyanavel XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; December Evekeo [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; February Focalin [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June Metadate CD [package insert]. Smyrna, GA: UCB, Inc.; February Metadate ER [package insert]. Smyrna, GA: UCB, Inc.; February Methylphenidate/Methylphenidate ER Tablets [package insert]. Hazelwood, MO: Mallinckrodt Inc.; April Methylin Chewable Tablets [package insert]. Florham Park, NJ: Shionogi Inc.; December Methylin Solution [package insert]. Florham Park, NJ: Shionogi Inc.; February ProCentra [package insert]. Newport, KY: Independence Pharmaceuticals, LLC; September QuilliChew ER [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; February Quillivant XR [package insert]. Monmouth Junction, NJ: Tris Pharma, Inc.; May Ritalin/Ritalin SR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; July Strattera [package insert]. Indianapolis, IN: Eli Lilly and Company; April Vyvanse [package insert]. Wayne, PA: Shire US Inc.; April Zenzedi [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC; May AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; [available with subscription]. Accessed November Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. [available with subscription]. Accessed November Practice Parameter for the Assessment and Treatment of Children and Adolescents with Attention- Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2007; 46(7): Accessed November American Academy of Pediatrics. ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2011; 128(5): Accessed November Cotempla XR-ODT [package insert]. Grand Prairie, TX: Neos Therapeutics, Inc.; June Mydayis [package insert]. Lexington, MA: Shire US Inc.; June Adzenys ER [package insert]. Grand Prairie, TX: Neos Therapeutics, LP.; September LIMIT CRITERIA One limit allowed per each strength 1 Month Limit* 3 Month Limit* Adderall 5 mg, 7.5 mg, 10 mg, 12.5 mg 90 tabs/ tabs/75 Adderall 15 mg, 20 mg 60 tabs/ tabs/75 Page 5 of 8
6 Adderall 30 mg 30 tabs/25 90 tabs/75 Adderall XR 5 mg, 10 mg 90 caps/ caps/75 Adderall XR 15 mg, 20 mg, 25 mg, 30 mg 30 caps/25 90 caps/75 Adzenys ER oral suspension 1.25 mg/ml 450 ml/ ml/75 Adzenys XR-ODT 3.1 mg, 6.3 mg, 9.4 mg 60 tabs/ tabs/75 Adzenys XR-ODT 12.5 mg, 15.7 mg mg 30 tabs/25 90 tabs/75 Aptensio XR 10 mg, 15 mg, 20 mg, 30 mg 60 caps/ caps/75 Aptensio XR 40 mg, 50 mg, 60 mg 30 caps/25 90 caps/75 Concerta 18 mg, 27 mg, 36 mg 60 tabs/ tabs/75 Concerta 54 mg 30 tabs/25 90 tabs/75 Cotempla XR 8.6 mg 60 tabs/ tabs/75 Cotempla XR 17.3 mg, 25.9 mg 60 tabs/ tabs/75 Daytrana Patch 10 mg, 15 mg, 20 mg, 30 mg 30 patches/25 90 patches/75 Desoxyn 5 mg 150 tabs/ tabs/75 Dextroamphetamine 2.5 mg, 5 mg, 7.5 mg, 10 mg 120 tabs/ tabs/75 Dextroamphetamine 15 mg, 20 mg 60 tabs/ tabs/75 Dextroamphetamine 30 mg 30 tabs/25 90 tabs/75 Dexedrine Spansule 5 mg, 10 mg 120 caps/ caps/75 Dexedrine Spansule 15 mg 60 caps/ caps/75 Dyanavel XR oral suspension 2.5 mg/ml 240 ml/ ml/75 Page 6 of 8
7 Evekeo 5 mg, 10 mg 120 tabs/ tabs/75 Focalin 2.5 mg, 5 mg 120 tabs/ tabs/75 Focalin 10 mg 60 tabs/ tabs/75 Focalin XR 5 mg, 10 mg, 15 mg, 20 mg 60 caps/ caps/75 Focalin XR 25 mg, 30 mg, 35 mg, 40 mg 30 caps/25 90 caps/75 Metadate CD 10 mg, 20 mg, 30 mg 60 caps/ caps/75 Metadate CD 40 mg, 50 mg, 60 mg 30 caps/25 90 caps/75 Methylin Chewable Tablets 2.5 mg, 5 mg or 10 mg 180 tabs/ tabs/75 Methylphenidate 5 mg, 10 mg 180 tabs/ tabs/75 Methylphenidate 20 mg 90 tabs/ tabs/75 Methylphenidate oral solution 5 mg/5 ml 1800 ml/ ml/75 Methylphenidate oral solution 10 mg/5 ml 900 ml/25 2,700 ml/75 Methylphenidate ER 10 mg, 20 mg 90 tabs/ tabs/75 Mydayis 12.5 mg, 25 mg 60 tabs/ tabs/75 Mydayis 37.5 mg, 50 mg 30 caps/25 90 caps/75 ProCentra oral solution 5 mg/5 ml 1200 ml/ ml/75 QuilliChew ER 20 mg, 30 mg 60 tabs/25 day 180 tabs/75 QuilliChew ER 40 mg 30 tabs/25 90 tabs/75 Quillivant XR oral suspension 25 mg/5 ml (5 mg/1 ml) 360 ml/ ml/75 Page 7 of 8
8 Ritalin LA 10 mg, 20 mg, 30 mg 60 caps/ caps/75 Ritalin LA 40 mg, 60 mg 30 caps/25 90 caps/75 Strattera 10 mg, 18 mg, 25 mg 120 caps/ caps/75 Strattera 40 mg 60 caps/ caps/75 Strattera 60 mg, 80 mg, 100 mg 30 caps/25 90 caps/75 Vyvanse 10 mg, 20 mg, 30 mg 60 caps/ caps/75 Vyvanse 40 mg, 50 mg, 60 mg, 70 mg 30 caps/25 90 caps/75 Zenzedi 2.5 mg, 5 mg, 7.5 mg, 10 mg 120 tabs/ tabs/75 Zenzedi 15 mg, 20 mg 60 tabs/ tabs/75 Zenzedi 30 mg 30 tabs/25 90 tabs/75 *The duration of 25 is used for a 30-day fill period and 75 is used for a 90-day fill period to allow time for refill processing. Page 8 of 8
UnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1020-6 Program Prior Authorization/Notification CNS Stimulants Medication Adderall* (amphetamine-dextroamphetamine mixed salts),
Central Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
OVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
Methylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 6 Last Review Date: September 15, 2017 Methylphenidate
ADHD Stimulant Step Therapy Program
ADHD Stimulant Step Therapy Program Policy Number: 5.01.592 Last Review: 7/2018 Origination: 7/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
Methylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Methylphenidates Page: 1 of 7 Last Review Date: November 30, 2018 Methylphenidate Dexmethylphenidate
Amphetamines
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.24 Subject: Amphetamines Page: 1 of 6 Last Review Date: December 8, 2017 Amphetamines Description
Clinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid
Clinical Policy: Reference Number: CP.PMN.XX Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
Amphetamines
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.24 Subject: Amphetamines Page: 1 of 6 Last Review Date: September 23, 2016 Amphetamines Description
GA KS KY LA MD NJ NV NY TN TX WA Applicable X N/A N/A X N/A X X X X X X N/A N/A X *FHK- Florida Healthy Kids. ADHD Narcolepsy
Override(s) Prior Authorization ADHD Narcolepsy Approval Duration 1 year *Louisiana, Washington and Maryland Medicaid See State Specific Information Below Medications Atomoxetine: Strattera generic Clonidine
Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (14).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 5 Last Review Date: December 2, 2016 Methylphenidate
Clinical Policy: CNS Stimulants Reference Number: CP.PMN.92 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid
Clinical Policy: Reference Number: CP.PMN.92 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
Clinical Policy: Atomoxetine (Strattera) Reference Number: CP.PST.17 Effective Date:
Clinical Policy: (Strattera) Reference Number: CP.PST.17 Effective Date: 08.01.17 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
Page: 1 of 5. Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (12).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.25 Page: 1 of 5 Last Review Date: June 19, 2015 Description Concerta / Daytrana / Metadate CD / Metadate
Off Label Uses: Amphetamines can be used as adjunctive therapy in the treatment of resistant depression (9).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.24 Subject: Amphetamines Page: 1 of 4 Last Review Date: June 19, 2015 Amphetamines Description Adderall
PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 3/15/18 SECTION: DRUGS LAST REVIEW DATE: 3/15/18 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
DYANAVEL XR (amphetamine) extended-release oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
QUANTITY LIMIT CRITERIA
QUANTITY LIMIT CRITERIA DRUG CLASS TRICYCLIC ANTIDEPRESSANT (TCA) AGENTS ELDERLY* BRAND NAME (generic) (amitriptyline) (amitriptyline/perphenazine) (amoxapine) ANAFRANIL (clomipramine) (chlordiazepoxide/amitriptyline)
35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: ADHD Medications P&T DATE 12/13/2017 CLASS: Psychiatric Disorders REVIEW HISTORY 12/16, 9/15, 5/12, 5/10, LOB: MCL (MONTH/YEAR)
Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants
AETNA BETTER HEALTH Pharmacy Prior Authorization Clinical Guideline for Attention Deficit Disorder/Attention Deficit Hyperactivity CNS Stimulants Formulary amphetamine/dextroamphetamine IR, ER (generic
Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/23/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6
in Children under Age 6 Level 0 Conduct comprehensive assessment and provide psychoeducation about ADHD, including clearly defined treatment expectations. Consider co-morbid developmental language disorder,
QUANTITY LIMIT CRITERIA
DRUG CLASS INHALATION BRAND NAME (generic) QUANTITY LIMIT CRITERIA SHORT ACTING BETA2-ADRENERGIC AGONIST ORAL (albuterol inhalation solution) PROAIR HFA PROAIR RESPICLICK PROVENTIL HFA VENTOLIN HFA XOPENEX
Cerebral Stimulant and ADHD Drugs Prior Authorization Request
Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 Cerebral Stimulant and ADHD Drugs Prior Authorization
ADHD Medications Table
Stimulants are the first line treatment of choice for ADHD followed by Non-Stimulants, then off-label medications. We are providing this list of medications so that you can be familiar with the common
STEP THERAPY CRITERIA
DRUG CLASS PRODUCTS) BRAND NAME (BRAND ONLY) (generic) STEP THERAPY CRITERIA ATYPICAL ANTIPSYCHOTICS (BRAND ONLY ABILIFY (AL TABLET & AL SOLUTION ONLY) (aripiprazole) FANAPT (BRAND ONLY) (iloperidone)
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market
ADHD Medications: Basics. David Benhayon MD, PhD
ADHD Medications: Basics David Benhayon MD, PhD Goals & Objectives Understand basic classes of stimulants and equivalents Be exposed to role of nonstimulant alternatives Discuss the role of therapy in
Big Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
Big Lots Behavioral Health. Prescribing Guidelines for Behavioral Health
Big Lots Behavioral Health Prescribing Guidelines for Behavioral Health Prescribing for Behavioral Health This document was developed by Nationwide Children s Hospital in conjunction with Partners For
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMA_10.11.7 Effective Date: 07.16 Last Review Date: 04.18 Line of Business: Cenpatico Medicaid Arizona Revision Log See Important Reminder at the end of this policy
The Use of ADHD Medication in the Pediatric Population
The Use of ADHD Medication in the Pediatric Population Shirin Madzhidova, PharmD Pediatric Pharmacotherapy Fellow Nova Southeastern University Objectives Discuss the importance of treatment with medications
A REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE
A REVIEW OF STIMULANTS FOR ADHD FOR THE PRIMARY CARE PROVIDER JAMES C. ASHWORTH MD MEDICAL DIRECTOR UNIVERSITY OF UTAH NEUROPSYCHIATRIC INSTITUTE OVERVIEW Review Stimulant Treatment for ADHD STIMULANTS
Parents Guide to ADHD Medications. Copyright Child Mind Institute
Copyright 2017. Child Mind Institute Children with attention-deficit hyperactivity disorder (ADHD) find it unusually difficult to concentrate on tasks, to pay attention, to sit still and to control impulsive
AD/HD is a mental disorder, and it often lasts from
short version10 WHAT WE KNOW Managing Medication for Adults with AD/HD AD/HD is a mental disorder, and it often lasts from childhood into adulthood. Medication is the basic part of treatment for adults.
Conversion from focalin xr to vyvanse
Conversion from focalin xr to vyvanse The Borg System is 100 % Conversion from focalin xr to vyvanse Sep 3, 2007. The importance of the 'conversion' dosing listed above relates to those people who may
PEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY Volume 22 Number 10 October 2016 T Amphetamine Orally Disintegrating Tablets: Another Option for the Treatment of Attention Deficit Hyperactivity Disorder Marcia L. Buck, PharmD,
Management of Pediatric Attention Deficit & Hyperactivity Disorder (ADHD) Clinical Practice Guideline MedStar Health
Management of Pediatric Attention Deficit & Hyperactivity Disorder (ADHD) Clinical Practice Guideline MedStar Health These guideli es are pro ided to assist physi ia s a d other clinicians in making decisions
DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA IMMEDIATE-RELEASE OPIOID ANALGESICS (BRAND AND GENERIC)*
Carelirst. +.V Family of health care plans cvs caremarktm DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA DRUG CLASS generic name, dosage form IMMEDIATE-RELEASE OPIOID ANALGESICS
STEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
Pharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines
Facts about ADHD drugs as treatment
Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)
Perspective Truth on ADHD & Medications. Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry
Perspective Truth on ADHD & Medications Thomas L. Matthews, M.D. Associate Dean of Student Affairs Professor of Psychiatry Disclosures National Institute of Health ADHD and Aggression Study Co- Investigator
Behavioral Health. Behavioral Health. Prescribing Guidelines
Behavioral Health Behavioral Health Prescribing Guidelines Attention Deficit/Hyperactivity Disorder (ADHD) Start with a first line medication, either from the methylphenidate or dextroamphetamine-amphetamine
Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
Drug Class Literature Scan: Attention Deficit Hyperactivity Disorder
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-2596
DURATION LIMIT CRITERIA ACETAMINOPHEN/ASPIRIN/IBUPROFEN CONTAINING OPIOID ANALGESICS (BRAND AND GENERIC) (acetaminophen and benzhydrocodone)
Carelirst. +.V Family of health care plans cvs caremarktm DRUG CLASS (generic)* DURATION LIMIT CRITERIA ACETAMINOPHEN/ASPIRIN/IBUPROFEN CONTAINING OPIOID ANALGESICS (BRAND AND GENERIC) (acetaminophen and
Pharmacotherapy of ADHD Across the Lifecycle: Stimulants
Pharmacotherapy of ADHD Across the Lifecycle: Stimulants Thomas J. Spencer, MD Massachusetts General Hospital Harvard Medical School Percent Change (Bmax/Kd) DVR Images Obtained with [ 11 C]Raclopride
ADHD: Management Update
4/5/17 Conflicts of Interest ADHD: Management Update I have no conflicts to disclose. Jennifer R. Walton, MD, MPH, FAAP April 7, 2017 ADHD: DSM-5 Definition Objectives To briefly review ADHD diagnostic
Dose Range. Dose Schedule. Child: 5-60 mg Over 50 kg:5-100 mg Focalin, child: mg Over 50 kg: mg. Focalin: 4-5 hrs.
MEDICATIONS FOR ADHD Group Main Use Medication Brand/ Form Dose Schedule Dose Range Most Common Side Effects for Group Pros for Group Cautions for Group methylphenidate Methylin Focalin (dexmethylphenidate)
Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Update 5 Report July 2015 The purpose of reports is to make available information regarding the comparative
Focalin compared to concerta
Focalin compared to concerta Search FREE SHIPPING how does focalin compared to concerta. Free shipping, quality, privacy, secure. how does focalin compared to concerta. Compare Ritalin vs. Focalin. Focalin
Attention Deficit Hyperactivity Disorder: Comparison of Medication Efficacy and Cost
Brigham Young University BYU ScholarsArchive All Student Publications 2014-06-20 Attention Deficit Hyperactivity Disorder: Comparison of Medication Efficacy and Cost Robert M. David Karlen E. Luthy Janelle
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Report Update 3 September 2009 Update 2: November 2007 Update 1: May 2006 Original Report: September 2005 The
ADHD Non-Stimulant Medications Step Therapy Program
ADHD Non-Stimulant Medications Step Therapy Program Policy Number: 5.01.596 Last Review: 7/2018 Origination: 07/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue
Ask The Shrink: ADHD
Ask The Shrink: ADHD Theodore A. Petti, MD Professor of Psychiatry Division of Child and Adolescent Psychiatry Robert Wood Johnson Medical School PPC Hub Psychiatrist Hackensack Meridian Hubs @ Saint Peter'
Half life of focalin xr
Cari untuk: Cari Cari Half life of focalin xr 24-12-2016 Find a comprehensive guide to possible side effects including common and rare side effects when taking Adderall XR (Amphetamine, Dextroamphetamine
John I. Bailey, Jr., MD
John I. Bailey, Jr., MD Mobile, Alabama 251 342-6443 ADHD and Related Conditions in Children & Adults www.calofmobile.com adddoc@bellsouth.net WHY I LEFT FAMILY PRACTICE FOR PSYCHIATRY Your insurance company
ADHD PRIMARY CARE PRINCIPLES FOR CHILD MENTAL HEALTH 27
ADHD PRIMARY CARE PRINCIPLES FOR CHILD MENTAL HEALTH 27 Considering ADHD diagnosis? Problem from inattention/hyperactivity Consider comorbidity or other diagnosis: Oppositional Defiant Disorder Conduct
Disorder (ADHD) in Adults
San Francisco Health Network Behavioral Health Services Medication Use Improvement Committee 1380 Howard St. 5 th Floor San Francisco, CA 94103 Edwin Lee Mayor Guideline for Evaluation and Treatment of
The Medical Letter. on Drugs and Therapeutics. Objective Drug Reviews Since Volume 57 March 16, Drugs for ADHD... p 37
The Medical Letter on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 57 March 16, 2015 ISSUE ISSUE No. 1433 1464 Volume 56 IN THIS ISSUE Drugs for ADHD... p 37 Important Copyright Message
Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor
The Carter Jenkins Center presents 1 Humberto Nagera M.D. Director, The Carter-Jenkins Center Psychoanalyst, Children, Adolescents and Adults Professor of Psychiatry at USF Professor Emeritus of Psychiatry
PAL Conference Cle Elum March 2015
Source Research Funding Books, Intellectual Property Advisor/ Consultant Speakers Bureau Employee In-kind Services (example: travel) Stock or Equity Honorarium or expenses for this presentation or meeting
Child & Adolescent Psychiatry (a brief overview)
Child & Adolescent Psychiatry (a brief overview) Lance Feldman, MD, FAPA, MBA, BSN Vice Chair Clinical Affairs, Department of Psychiatry Affiliate Clinical Assistant Professor, University of South Carolina
Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy
BENEFIT APPLICATION DRUG POLICY Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy Benefit determinations are based on the applicable
ADHD: A Focus On Drug Therapy
ADHD: A Focus On Drug Therapy MARY WORTHINGTON, PHARM.D., BCPS MCWHORTER SCHOOL OF PHARMACY BIRMINGHAM, ALABAMA SEPTEMBER 13, 2013 Outpatient Prescription Drug Utilization in US Children, 2002-2010 90
QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA
DRUG CLASS QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME (generic) ARYMO ER (morphine sulfate extended-release tablets) AVINZA (morphine extended-release
Stimulants. The psychostimulants, or more simply known as stimulants, are used primarily in treating attention-deficit/ Dosing Information
Adderall and Adderall-XR (amphetamine mixtures) Concerta (methylphenidate, controlled Dexedrine, Dexedrine Spansules (dextroamphetamine) Focalin (dexmethylphenidate) Metadate, Metadate-ER, and Metadate-CD
Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: NH.PMN.36 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: NH.PMN.36 Effective Date: 02.09 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy
Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP.PMN.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vyvanse) Reference Number: CP.PMN.121 Effective Date: 02.01.09 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
F O C A L I N P R O D U C T M O N O G R A P H C H NO HCl
FOCALIN PRODUCT MONOGRAPH C 14 H 19 NO 2 HCl FOCALIN PRODUCT MONOGRAPH C 14 H 19 NO 2 HCl CONTENTS Introduction..........................................................................1 Background of
Relative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
North Dakota Medicaid. Drug Utilization Review Board. Drug Class Review
North Dakota Medicaid Drug Utilization Review Board Drug Class Review Attention Deficit Hyperactivity Disorder (ADHD) Agents Prepared by Health Information Designs, Inc. 1 North Dakota Department of Social
We ll Be Discussing. Pregnancy 4/24/2013
Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free monthly e-newsletter? We ll Be Discussing The safety and efficacy track
Attention-deficit/hyperactivity disorder (ADHD) is characterized
THE JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION Treatment of Adults With Attention-Deficit/Hyperactivity Disorder David A. Baron, DO, MSEd Michele T. Pato, MD Rebecca L. Cyr, BA Attention-deficit/hyperactivity
What are the most common signs of ADHD? And what are the most common medication interventions?
What are the most common signs of ADHD? And what are the most common medication interventions? Bennett Gertz, MD, FAAP Developmental Behavioral Pediatrician Children s Developmental Health Services Albertina
Clinical Policy: Lisdexamfetamine (Vyvanse) Reference Number: CP.PMN.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vyvanse) Reference Number: CP.PMN.121 Effective Date: 02.01.09 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
Focusing in on Adult ADHD
Focusing in on Adult ADHD Diagnosis, Psychopharmacology, and Therapeutic Interventions Sharon Praissman Fisher, MS, APRN-A, APRN-PMHNP Balance Point Wellness Disclosures I have no financial/professional
Focusing in on Adult ADHD
Focusing in on Adult ADHD Diagnosis, Psychopharmacology, and Therapeutic Interventions Sharon Praissman Fisher, MS, APRN-A, APRN-PMHNP Balance Point Wellness Disclosures I have no financial/professional
2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
10/30/2018. Learning Objectives. Mental Health/Disability Overview. Mental Health/Disability Overview. Attention Deficit Hyperactivity Disorder
Assessment and Management of ADHD in Children and Teens in Primary Care Susan Van Cleve DNP, APRN, CPNP-PC, PMHS, FAANP, FAAN Clinical Professor and Director of the Primary Care Pediatric Nurse Practitioner
BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
Psychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition
Psychopharmacology for Treatment of ADHD and ADHD with other co-existing psychiatric condition Presented by Cat Dang, D.O Medical Director - Insightful Minds, Inc. Objectives Evaluation process Pharmacology
QUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
Drug Class Review Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder Final Report Update 3 October 2009 Update 2: November 2007 Update 1: May 2006 Original Report: September 2005 The
Adderall to focalin conversion
Search Search Adderall to focalin conversion Methylphenidate is generally well tolerated. The most commonly observed adverse effects with a frequency greater than placebo include appetite loss, dry mouth.
Conversion table methylphenidate to vyvanse
P ford residence southampton, ny Conversion table methylphenidate to vyvanse Lisdexamfetamine dimesylate is converted to dextoamphetamine and L- lysine, which is of ADDERALL XR (10, 20, or 30 mg), Vyvanse
ADHD: A Life Script from Conception to Adulthood
Page 1 Attention Deficit Hyperactivity Disorder A Life Script from Conception to Adulthood A life script from conception to adulthood. Elizabeth A. Montagnese, M.D. Child and Adult Psychiatrist Speaker:
PL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
Child/Adolescent Attention-Deficit/Hyperactivity Disorder
Child/Adolescent Attention-Deficit/Hyperactivity Disorder NATIONAL GUIDELINE SUMMARY This evidence-based guideline summary is based on the 202 National Child/Adolescent Attention-Defict/ Hyperactivity
18 PRIMARY CARE PRINCIPLES FOR CHILD MENTAL HEALTH ADHD
18 PRIMARY CARE PRINCIPLES FOR CHILD MENTAL HEALTH ADHD Considering ADHD diagnosis? Problem from inattention/hyperactivity Consider comorbidity or other diagnosis: Oppositional Defiant Disorder Conduct
generics) ER, Methylin and generic) prior authorization
ADHD Non-Stimulant Medications Step Therapy Program Policy Number: 5.01.596 Origination: 07/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for brand name non-stimulant
ADHD: Medications and Behavioral Interventions
ADHD: Medications and Behavioral Interventions PAL Conference June 23 rd 2018 Erin Dillon-Naftolin, MD Child and Adolescent Psychiatrist Psychiatry and Behavioral Medicine Seattle Children s Hospital Disclosures
STATUS EPILEPTICUS IN CHILDREN
STATUS EPILEPTICUS IN CHILDREN Kathy Hunter Sprott, PharmD, BCPS, BCPPS Clinical Pharmacy Specialist Pediatric Transplant and General Pediatrics February 20 th, 2019 Disclosure Statement I have no financial
Attention Deficit Hyperactivity Disorder State of the Art. Christopher Okiishi, MD
Attention Deficit Hyperactivity Disorder State of the Art Christopher Okiishi, MD What is ADHD? Three subtypes: Inattentive (under diagnosed, esp. in girls) Hyperactive Impulsive Combined Impairments must
ADHD Medications & How They Work. Gail C. Rodin, Ph.D. January 21, 2008
ADHD Medications & How They Work Gail C. Rodin, Ph.D. January 21, 2008 Agenda How the (ADHD) Brain Works (or doesn t) Neurons and neurotransmitters NE & DA: the major players in ADHD Channel vs. state
ADHD:Updates and Practical Suggestions
:Updates and Practical Suggestions Elizabeth Reeve MD HealthPartners Medical Group Disclosure I have no financial disclosures I may be talking about non FDA approved indications for medications Elizabeth.A.Reeve@HealthPartners.com